A5085662334- Health Systems, Economic Evaluations, Quality of Life
- Growth Hormone and Insulin-like Growth Factors
- Childhood Cancer Survivors' Quality of Life
- Trace Elements in Health
- Chemotherapy-induced cardiotoxicity and mitigation
- Multiple Myeloma Research and Treatments
- Meta-analysis and systematic reviews
- Iron Metabolism and Disorders
- Multiple Sclerosis Research Studies
- HIV/AIDS drug development and treatment
- Cardiac pacing and defibrillation studies
- Intraperitoneal and Appendiceal Malignancies
- Chronic Myeloid Leukemia Treatments
- Anesthesia and Sedative Agents
- Pituitary Gland Disorders and Treatments
- Peptidase Inhibition and Analysis
- Appendicitis Diagnosis and Management
- Cardiac Arrhythmias and Treatments
- Healthcare Systems and Public Health
- Child Nutrition and Water Access
- Lipid metabolism and disorders
- Diet and metabolism studies
- Biomedical Ethics and Regulation
- Cardiac electrophysiology and arrhythmias
- Life Cycle Costing Analysis
Dalhousie University
2023
University of Southampton
2001-2013
Perth Royal Infirmary
2010-2011
Southampton City Council
2011
National Institute for Health Research
2011
Wessex Institute of Technology
2000-2009
University College London
2008
Nottinghamshire County Council
2000
Keele University
2000
University of Birmingham
2000
Mantel's extension of Mantel-Haenzel procedure * Used only in tables and appendices 1. Prevention disease progression relapse rates.This is the aim modifying (or immunomodulatory) drugs.The drugs examined this report are: azathioprine, beta interferon (IFβ), cladribine, cyclophosphamide, glatiramer, intravenous immunoglobulin, methotrexate mitoxantrone.Azathioprine licensed for use all forms MS.IFβ-1a 1b are relapsing-remitting MS secondary progressive MS, IFβ-1b MS.Cladribine, mitoxantrone...
This paper presents a summary of the evidence review group (ERG) report into clinical effectiveness and cost-effectiveness bortezomib for treatment multiple myeloma patients at first relapse beyond, in accordance with licensed indication, based upon submission from Ortho Biotech to National Institute Health Clinical Excellence (NICE) as part single technology appraisal (STA) process. The outcomes stated manufacturer’s definition decision problem were time disease progression, response rate,...
PROPOSED SERVICE: The service proposed is the use of implantable cardioverter defibrillators (ICDs) in management risk factors leading to sudden cardiac death (SCD). ICDs are similar size a pacemaker and intended prevent due life-threatening ventricular tachyarrhythmias. SCD occurs approximately 100,000 people annually UK usually tachyarrhythmia. Increasing numbers surviving first episode tachyarrhythmia at high further episodes. Standard treatments for those have been anti-arrhythmic drugs,...